Innocan Pharma's Latest Breakthrough in CBD Delivery System
Innocan Pharma's Exciting Research on LPT-CBD
Innocan Pharma Corporation (CSE: INNPF), a leading innovator in the pharmaceutical and biotechnology industries, is thrilled to share the acceptance of its research article, "Liposomal-Cannabidiol Injection: Preliminary Insights into Pharmacokinetics and Safety Characteristics in Göttingen Minipigs and Rabbits" in the prestigious journal Precision Nanomedicine. This study highlights the positive outcomes from the administration of LPT-CBD, showcasing prolonged release and an encouraging safety profile following a single subcutaneous dose in minipigs.
Important Corporate Updates from Innocan Pharma
Leadership Transition
Ron Mayron, the Executive Chairman and a Director of Innocan, has officially stepped down as of July 1, 2025. However, he will continue to support the organization for an additional three months in a consulting role. Transitioning into the Chair position, Iris Bincovich, an existing Director and the Chief Executive Officer, has expressed gratitude to Ron for his substantial contributions towards the company’s growth and success.
Strategic Grants of RSUs and Stock Options
In a strategic move, on July 2, 2025, Innocan granted 23,050,000 Restricted Share Units (RSUs) to certain directors, officers, employees, and consultants, to be paid in common shares once specific milestone-based conditions are met. On the same day, the company also awarded 1,950,000 stock options at an exercise price of $0.225, with a five-year expiration, marking a focus on elevating employee engagement and commitment through ownership opportunities.
Industry Leading Innovations in Health and Wellness
Innocan is not just about groundbreaking research but also about implementing those findings into practical solutions. The company has pioneered a CBD-loaded liposome drug delivery platform that ensures precise dosing and controlled release, contributing significantly to non-opioid pain management solutions. In addition, Innocan has developed an extensive range of self-care and beauty products under its wellness sector, aiming to foster healthier lifestyle choices among consumers.
Contact Information and Further Details
For additional inquiries or information on Innocan Pharma Corporation, please contact the following:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
Frequently Asked Questions
What recent research has Innocan Pharma published?
Innocan Pharma's latest research focuses on the safety and pharmacokinetics of its LPT-CBD formulation, with promising results from studies conducted on minipigs.
Who has stepped down from Innocan's leadership?
Ron Mayron has resigned as Executive Chairman and Director but will assist the company as a consultant for three more months.
What are RSUs and stock options?
RSUs (Restricted Share Units) and stock options are forms of employee compensation that provide advantages tied to the company's stock performance.
What products does Innocan Pharma offer?
Innocan offers innovative pharmaceutical solutions, particularly a CBD drug delivery platform, along with self-care and beauty products for holistic wellness.
How can I learn more about Innocan Pharma?
For further information, you can contact their CEO or visit their official website for a comprehensive overview of their offerings and updates.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
